AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02071420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email Intervention
Description: Participants of both arms will receive three emails per week for 16 weeks. Messages will be consistent with what they hear in the ergonomic intervention (e.g., encourage taking breaks from sitting at work and adjusting posture to be in line with ergonomic principles).
Study NCT02071420 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application.
Study NCT02071420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application.
Study NCT03411200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal and exercise-based intervention
Description: The multimodal and exercise-based intervention is comprised of:~1. Supervised and group-based exercise two times a week (60 minutes per session). The program consists of warm-up, exercises for balance and flexibility, progressive resistance training, and stretching and relaxation.~2. Individualized activity program based on step counts (with activity tracker). Based on each participant's starting point, preferences and motivation, an individualized program will be composed. Evaluation and goal-setting will be conducted once weekly.~3. Nurse-led supportive and motivational counseling; each participant will be invited to two sessions of counseling (in week 1 + 6). Each session will be based on a holistic assessment of each participant's life situation. Advice and counseling will be provided based on identified problems and needs.~4. A nutritional supplement (protein bar or drink) will be served to participants immediately after the supervised exercise session.
Study NCT01527513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (BIA 2-093)
Description: Eslicarbazepine acetate (ESL) tablets 200 mg and the matching placebo will be supplied. Treatments will be administered by oral route, once-daily, in the evening. The dose will be rounded to the nearest 100 mg unit. Half tablets may be used for dose adjustment if necessary.
Study NCT01213849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 50 mcg (4 inhalations)
Description: 4 inhalations of 50 mcg strength
Study NCT01213849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 mcg (4 inhalations)
Description: 4 inhalations of 100 mcg strength
Study NCT01527513 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatments will be administered by oral route, once-daily, in the evening.
Study NCT01384331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marvelon
Description: 7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules~* 21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~* 21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days~* 21 days daily oral placebo capsules Treatment will be for one cycle of 21 days
Study NCT01384331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Marvelon
Description: 7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules~* 21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~* 21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days~* 21 days daily oral placebo capsules Treatment will be for one cycle of 21 days
Study NCT02695823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound measurements of the optic nerve sheath diameter and intracranial Doppler, at 4 time points during surgery (incision, anhepatic phase + 30 min, declamping + 5 min, declamping + 30 min), and at day 1 and day 5 after surgery, to detect presence of intracranial hypertension.~Search of any neurological complication during the 5 postoperative days.
Study NCT01213849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 200 mcg (4 inhalations)
Description: 4 inhalations of 200 mcg strength
Study NCT01213849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol 25 mcg (4 inhalations)
Description: 4 inhalations of 25 mcg strength
Study NCT00869531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wholegrain
Description: wholegrain wheat vs. refined wheat products
Study NCT04458311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Supplied as 125 mg tablets
Study NCT00869531 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: refined wheat
Description: refined wheat products
Study NCT01493206 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intraoperative radiotherapy
Description: intraoperative radiotherapy
Study NCT04458311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: Tildrakizumab will be supplied in single-use 100 mg/mL glass vials intended for IV infusion.
Study NCT03696576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMST
Description: Training of the respiratory system muscles using the EMST device.
Study NCT04512209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Patients will undergo an MR scan before undergoing cytoreductive surgery. If neoadjuvant chemotherapy is administered, an extra MR scan is planned before the start of the neoadjuvant chemotherapy.~During surgery, tissue samples will be taken for interstitial fluid pressure (IFP) measurement, immunohistochemistry (IHC) and characterization of biophysical properties (viscoelastic properties and hydraulic conductivity).
Study NCT03388333 — intervention group
Intervention type: PROCEDURE
Intervention: Catheter Ablation
Study NCT03696576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PhoRTE
Description: Completing of PhoRTE voice therapy.
Study NCT03696576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PhoRTE
Description: Completing of PhoRTE voice therapy.
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: Target: m-TOR
Study NCT01137006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-20D7S (Cohort 1A)
Description: 5 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants, then enrollment into Cohort 2A.
Study NCT01137006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-20D7S (Cohort 2A)
Description: 10 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2A, then enrollment into Cohort 3A.
Study NCT01137006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-20D7S (Cohort 3A)
Description: 20 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 3A, then enrollment into Cohort 4A.
Study NCT01137006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-20D7S (Cohort 4A)
Description: 30 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.
Study NCT02480543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol (cytotec)
Study NCT01137006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-20D7S (Cohort 1B)
Description: 10 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants in Cohort 1B, then enrollment into Cohort 2B.
Study NCT01137006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-20D7S (Cohort 2B)
Description: 20 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2B, then enrollment into Cohort 3B.
Study NCT01137006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-20D7S (Cohort 3B)
Description: 30 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.
Study NCT01332006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrabone injection
Description: All adults patients with hematological malignancies, lacking a HLA matched donor fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
Study NCT01332006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-bone cord blood hematopoietic stem cell transplantation
Study NCT01332006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-bone cord blood hematopoietic stem cell transplantation
Description: Intra-bone injection of CB hematopoietic SCs after conditioning regimen
Study NCT00850135 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The Seven Continuous Glucose Monitoring System
Description: Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
Study NCT01064466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETOPOSIDE - Study
Description: Etoposide Capsule
Study NCT01282957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive Group I
Description: Lottery with 1 in 100 odds of $100 and 18 in 100 odds of $10. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
Study NCT01282957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive Group II
Description: Lottery with 1 in 100 odds of $50 and 18 in 100 odds of $5. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
Study NCT03245944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early Angioplasty
Description: Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Early means pt will get the procedure at 6 weeks from time of initiation of AVFs
Study NCT03245944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: late Angioplasty
Description: Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Late means the angioplasty is done at 3 months from time of AVF creation if still immature at that time.
Study NCT02640430 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: 20 minutes, twice a day for 10 sessions
Study NCT02640430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free Aspire
Description: 20 minutes, twice a day for 10 sessions
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: Target: EGFR
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Target: AKT
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8931
Description: Target: HER2, EGFR
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Target: MEK
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Target: VEGF, EGFR
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: target: Androgen receptor
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Target: PARP
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anthracyclines
Description: DNA intercalation
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxanes
Description: Target: mitotic tubulin and microtubules
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Alkylating agents
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DNA intercalators
Description: DNA intercalators
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: DNA intercalators
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinca alkaloids
Description: Target: mitotic tubulin and microtubules
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum based chemotherapies
Description: Platinum based chemotherapies
Study NCT04135391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: All recruited subjects underwent 36 times of moderate-intensity continuous training (MICT) at 60% of peak oxygen consumption (VO2peak) for 30 mins, and 10or had high-intensity interval training (HIIT) at alternative 80% and 40% VO2peak with the same training times and duration.
Study NCT04677803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT200
Description: BT200 is a PEGylated synthetic RNA oligonucleotide
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Target: VEGF
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Alkylating agents
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Microtubule modulator
Study NCT02299999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Target: PD-L1
Study NCT03576885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled nitric oxide
Description: inhaled nitric oxide will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
Study NCT03576885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
Study NCT01818128 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neutral shape of bronchial tip
Description: Intubation is performed without transforming the shape of the bonchial tipof a double lumen tube.
Study NCT01818128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bent shape of bronchial tip
Description: Intubation is performed with the double lumen tube, which bronchial tip has been bent 45 degrees and maintained for 5 min.
Study NCT02652052 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care - Observation Only
Description: Control Arm - Observation only
Study NCT02652052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2: Quercetin
Description: Quercetin - take four 250mg capsules daily (total 1000 mg daily) for 3 consecutive days.
Study NCT02652052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2: Dasatinib
Description: Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days
Study NCT04054193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant Dimeglumine
Description: Participants received IV fosaprepitant dimeglumine ≤115 mg on Day 1 and ≤80 mg on Days 2 and 3 (dose adjusted for age).
Study NCT04054193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-HT3 antagonist
Description: All participants received an oral 5-hydroxytryptamine (serotonin; \[5-HT\]) 3 receptor antagonist on Day 1 and had the option to take on Days 2-3. The dose was as per product label or standard of care.
Study NCT04054193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants received optional oral dexamethasone at the investigator's discretion according to product label or standard of care.
Study NCT04096066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: * 20 mg/m2 IV on day 1 of cycle 1 enhanced to 56 mg/m2 on days 8, and 15 of cycle 1;~* 56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;~* 56 mg/m2 IV on days 1 and 15 from cycle 13 and onwards.
Study NCT04096066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: - 25 mg orally on days 1-21 of each cycle.
Study NCT00355615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: oral
Study NCT04096066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: - 25 mg orally on days 1-21 of each cycle.
Study NCT04096066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: - 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.~For patients >75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle.
Study NCT04096066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: - 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.~For patients >75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle.
Study NCT01598753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: 50 mg tablets titrated up to 2 tablets four times per day for a maximum dose of 400mg per day.~Minimum accepted dose of 200mg per day
Study NCT01598753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmacological inactive tablet, 50mg tablets titrated to 2 tabs per day up to 400mg
Study NCT01598753 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy for FM
Description: Subjects will be seen for 8 weekly 50 minute sessions of Cognitive Behavior Therapy that has been specifically tailored for Fibromyalgia patients.
Study NCT01598753 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Education
Description: Subjects will receive 8 weekly 50 minute sessions of Health Education on Fibromyalgia
Study NCT02426190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill
Description: The intervention is to ask study participants to ambulate using an anti-gravity treadmill that integrates patented, NASA Differential Air Pressure (DAP) technology -- a precise air calibration system -- to uniformly reduce gravitational load and body weight during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
Study NCT02426190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PENS - neuro-muscular stimulation
Description: The intervention is to ask study participants to warm up using Patterned Electrical Neuromuscular Stimulation (PENS) - that closely replicates the body's normal muscle and nerve firing patterns -- on his/her surgical leg in conjunction with a recumbent bike or a Nu-step bike during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
Study NCT02426190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-gravity treadmill & PENS - neuro-muscular stimulation
Description: The intervention is to ask study participants to ambulate using an anti-gravity treadmill in conjunction with use of Patterned Electrical Neuromuscular Stimulation (PENS) during the warm-up phase of an outpatient physical therapy following a single total knee replacement.